Pharma supply planning under recurrent disruption: sensing must lead to executable pivots
When disruption becomes routine
In an interview published by Pharmaceutical Commerce on October 7, Freehand co-founder and CEO Nitin Jayakrishnan describes disruptions that were once exceptional as recurring much more frequently. He connects this environment to the succession of global shocks affecting international supply chains and argues that organizations are moving toward operating models designed to sense changes and pivot.
The planning implication
This viewpoint raises a practical question for pharmaceutical manufacturers and distributors: can the planning process change course before the next formal planning cycle? A monthly consensus plan remains useful for direction and resource alignment, but it cannot by itself resolve every near-term interruption.
Dataleo's interpretation is that resilient planning requires a defined route from a changed supply assumption to a revised operational decision. That could mean assessing alternative supply allocations, production priorities or inventory deployment options, subject to the constraints of the actual pharmaceutical network. These examples are analytical implications, not reported implementations from the interview.
What a credible pivot requires
Recognizing disruption is not equivalent to having a feasible response. A candidate scenario must account for the supply that is genuinely available, timing dependencies and any applicable operating restrictions before it changes commitments. Decision rights also matter: an escalation process that takes longer than the available response window defeats the purpose of earlier sensing.
Limits of the evidence
The accessible interview supports a qualitative argument about disruption frequency and adaptability. It does not establish that any particular planning software, AI system or operating model has delivered superior pharmaceutical supply chain performance. The practical lesson is to examine the time between detection, scenario evaluation and an executable decision rather than treating resilience as a technology label.